BACKGROUND: In 2003, this laboratory published an account of the human mast cell line LAD2 (Laboratory of Allergic Diseases 2) that expressed FcεRI, responded to recombinant human stem cell factor (rhSCF) and resembled CD34+-derived human mast cells. LAD2 cells have now been distributed worldwide. To study the impact of this transfer, we analyzed the number of investigators receiving LAD2 cells and resulting publications. METHODS: Records maintained in our laboratory, the Technology Transfer and Intellectual Property Office and Office of Technology Transfer, were reviewed for material transfer agreements (MTAs) and licensing agreements (LAs). Journals and impact factors were obtained from PubMed.gov by cross-referencing LAD2 and human mast cells from 2003 through November 2013. RESULTS: Over 300 MTAs and 40 LAs were approved. LAD2 cells were shipped to over 30 countries. More than 80 papers have been published in journals with impact factors from 1.31 to 13.21. Intended uses include the study of receptors, degranulation, and cell signaling. LAD2 cells continue to express described markers and have consistent FcεR1-mediated degranulation. CONCLUSIONS: Success of the LAD2 line reflects the demand for a human mast cell line in research, the uniqueness of this cell line, and that it continues to exhibit minimal variation from its original description. We hope that the awareness of the impact of this cell line on mast cell research will encourage others to develop and distribute other similar cell lines with additional characteristics so as to address the limitations of depending on the study of cultured human mast cells from tissues.
BACKGROUND: In 2003, this laboratory published an account of the human mast cell line LAD2 (Laboratory of Allergic Diseases 2) that expressed FcεRI, responded to recombinant humanstem cell factor (rhSCF) and resembled CD34+-derived human mast cells. LAD2 cells have now been distributed worldwide. To study the impact of this transfer, we analyzed the number of investigators receiving LAD2 cells and resulting publications. METHODS: Records maintained in our laboratory, the Technology Transfer and Intellectual Property Office and Office of Technology Transfer, were reviewed for material transfer agreements (MTAs) and licensing agreements (LAs). Journals and impact factors were obtained from PubMed.gov by cross-referencing LAD2 and human mast cells from 2003 through November 2013. RESULTS: Over 300 MTAs and 40 LAs were approved. LAD2 cells were shipped to over 30 countries. More than 80 papers have been published in journals with impact factors from 1.31 to 13.21. Intended uses include the study of receptors, degranulation, and cell signaling. LAD2 cells continue to express described markers and have consistent FcεR1-mediated degranulation. CONCLUSIONS: Success of the LAD2 line reflects the demand for a human mast cell line in research, the uniqueness of this cell line, and that it continues to exhibit minimal variation from its original description. We hope that the awareness of the impact of this cell line on mast cell research will encourage others to develop and distribute other similar cell lines with additional characteristics so as to address the limitations of depending on the study of cultured human mast cells from tissues.
Authors: Eunice Ching Chan; Yun Bai; Geethani Bandara; Olga Simakova; Erica Brittain; Linda Scott; Kimberly D Dyer; Amy D Klion; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson Journal: Exp Hematol Date: 2013-06-04 Impact factor: 3.084
Authors: Tomonobu Ito; Daniel Smrž; Mi-Yeon Jung; Geethani Bandara; Avanti Desai; Šárka Smržová; Hye Sun Kuehn; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan Journal: J Immunol Date: 2012-04-23 Impact factor: 5.422
Authors: Andrea M Siegel; Kelly D Stone; Glenn Cruse; Monica G Lawrence; Ana Olivera; Mi-yeon Jung; John S Barber; Alexandra F Freeman; Steven M Holland; Michelle O'Brien; Nina Jones; Celeste G Nelson; Laura B Wisch; Heidi H Kong; Avanti Desai; Orly Farber; Alasdair M Gilfillan; Juan Rivera; Joshua D Milner Journal: J Allergy Clin Immunol Date: 2013-11-01 Impact factor: 10.793
Authors: Arnold S Kirshenbaum; Cem Akin; Yalin Wu; Menachem Rottem; Julie P Goff; Michael A Beaven; V Koneti Rao; Dean D Metcalfe Journal: Leuk Res Date: 2003-08 Impact factor: 3.156
Authors: Nicolas Castaño; Seth C Cordts; Kari C Nadeau; Mindy Tsai; Stephen J Galli; Sindy K Y Tang Journal: Biomicrofluidics Date: 2020-04-03 Impact factor: 2.800
Authors: Emily W Ozpinar; Ariana L Frey; Greer K Arthur; Camilo Mora-Navarro; Andreea Biehl; Douglas B Snider; Glenn Cruse; Donald O Freytes Journal: Tissue Eng Part A Date: 2020-11-19 Impact factor: 4.080
Authors: Arnold S Kirshenbaum; Glenn Cruse; Avanti Desai; Geethani Bandara; Maarten Leerkes; Chyi-Chia R Lee; Elizabeth R Fischer; Kevin J O'Brien; Bernadette R Gochuico; Kelly Stone; William A Gahl; Dean D Metcalfe Journal: PLoS One Date: 2016-07-26 Impact factor: 3.240